Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07038096CT.gov ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | — | Recruiting | — | — | — |
NCT06283719CT.gov Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06440057CT.gov Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. | — | Recruiting | — | — | — |
NCT05978284CT.gov Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| zg006 (this asset) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | P1/2 | CC · 45 |
| Etoposide | National Cancer Institute (NCI) | P2 | B |
| Everolimus | AIO-Studien-gGmbH | P2 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Novartis Pharmaceuticals | P2 | B |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P2 | B |
| Tarlatamab | National Cancer Institute (NCI) | P2 | B |
| Lurbinectedin | Jazz Pharmaceuticals | P2 | B |
| Pembrolizumab | Ochsner Health System | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | B |
+42 more in the Neuroendocrine Carcinoma cohort
Other indications for zg006
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Small Cell Lung Carcinoma | — | P3 | B · 60 |
| Prostate Neuroendocrine Neoplasm | — | P2 | CCC · 53 |
| Neoplasm | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- EtoposideNational Cancer Institute (NCI)B
- EverolimusAIO-Studien-gGmbHB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-Novartis PharmaceuticalsB
- Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)B
- TarlatamabNational Cancer Institute (NCI)B
Citation
Floatz Terminal. zg006 in Neuroendocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/zg006-neuroendocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →